Buyout Investments

Synerlab

Activity

SynerLAB is one of the leading French Contract Manufacturing Organisations of generic and ethical pharmaceutical products (i.e. patent protected and prescription sales) supplying laboratories. SynerLAB focuses on dry pharmaceutical forms including capsules, tablets, powders, granules etc and liquid forms such as syrups and mixtures etc, at its two production sites in Erstein (“Laboratoires BTT”) and Vernouillet (“Laboratoires Sophartex”). The group has a reputation among its pharmaceutical industry customers for its reactivity, flexibility and proven know-how in certain types of drugs and packaging. Backed by 520 employees, SynerLAB posted 2006 revenues of over €67 million largely in France.

Strategy

This LBO transaction was based on the existing management team. With AXA Private Equity’s support, SynerLAB seeks organic growth in a promising market over the coming years. It will aim to exploit its capacity to offer new services to customers and its potential for growth on certain export markets. The group also intends to grow via strategic acquisitions.